Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanz Ponders Photofrin Sale As It Weighs Deals in Europe

Executive Summary

Advanz Pharma is considering slimming down its US operations as it searches for global product deals and company acquisitions in western Europe to restore sales growth.

You may also be interested in...



UK’s CMA Doubles Down On Liothyronine Objections

The UK’s CMA has reiterated its belief that Advanz Pharma charged excessive and unfair prices for liothyronine in the UK, following a separate ruling that provided detailed guidance on how such matters should be evaluated.

Advanz Embarks On Strategic Plan By Buying Two Eisai Brands

By paying just over US$33 million for two Eisai legacy brands, Advanz Pharma is starting to deliver on its strategy to acquire and license a portfolio of niche off-patent medicines.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Topics

UsernamePublicRestriction

Register

GB140183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel